Page last updated: 2024-11-11

tekturna

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6918427
CHEMBL ID3545059
CHEBI ID53777
SCHEMBL ID187762
MeSH IDM0505065

Synonyms (74)

Synonym
aliskiren (hemifumarate)
HY-12177
cgp-60536
sprimeo
enviage
tekturna
cgp-60536b
riprazo
spp-100b
tekturna (tn)
D06412
aliskiren hemifumarate ,
aliskiren fumarate (jan/usan)
bis(2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methyl-2-(1-methylethyl)nonanamide) (2e)-but-2-enedioate
benzeneoctanamide, delta-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphas,gammas,deltas,zetas)-, (2e)-2-butenedioate (2:1) (salt)
aliskiren fumarate [usan]
CHEBI:53777 ,
bis{(2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide} (2e)-but-2-enedioate
unii-c8a0p8g029
nsc 759185
aliskiren fumarate [usan:jan]
c8a0p8g029 ,
nsc-759185
aliskiren hemifumarate component of sprimeo-hct
aliskiren hemifumarate [mi]
rasilamlo component aliskiren hemifumarate
aliskiren hemifumarate component of raprazo-hct
aliskiren hemifumarate component of tekamlo
aliskiren (as fumarate)
amturnide component aliskiren hemifumarate
tekamlo component aliskiren hemifumarate
aliskiren fumarate [mart.]
aliskiren fumarate [jan]
rasitrio component aliskiren hemifumarate
aliskiren hemifumarate component of rasilez-hct
sprimeo-hct component aliskiren hemifumarate
tekturna hct component aliskiren hemifumarate
aliskiren hemifumarate [orange book]
aliskiren fumarate [who-dd]
aliskiren hemifumarate component of rasitrio
valturna component aliskiren hemifumarate
aliskiren hemifumarate component of rasilamlo
rasilez-hct component aliskiren hemifumarate
bis(2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide] (2e)-but-2-enedioate
aliskiren hemifumarate [vandf]
aliskiren hemifumarate component of valturna
aliskiren hemifumarate component of tekturna hct
raprazo-hct component aliskiren hemifumarate
aliskiren hemifumarate component of amturnide
CS-0729
S12129
AKOS015896419
S2199
SCHEMBL187762
KS-1395
KLRSDBSKUSSCGU-KRQUFFFQSA-N
(?s,?s,?s,?s)-?-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-?-hydroxy-4-methoxy-3-(3-methoxypropoxy)-?,?-bis(1-methylethyl)benzeneoctanamide hemifumarate
(2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide hemifumarate
CHEMBL3545059
bis((2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide) fumarate
SW222231-1
Q27124205
cgp 60536 (hemifumarate);cgp60536b (hemifumarate);spp 100 (hemifumarate)
EN300-122378
bis((2s,4s,5s,7s)-5-amino-n-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide); but-2-enedioic acid
(2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide;(e)-but-2-enedioic acid
CCG-270658
BA164146
aliskiren hemifumarate- bio-x
Z1541759907
aliskiren fumarate (mart.)
bis((2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methyl-2-(propan-2-yl)nonanamide) (2e)-but-2-enedioate
bis((2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methyl-2-(1-methylethyl)nonanamide) (2e)-but-2-enedioate
bis((2s,4s,5s,7s)-5-amino-n-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-(1-methylethyl)-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide) monofumarate

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans."( Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
Baldwin, JJ; Bukhtiyarov, Y; Cacatian, S; Claremon, DA; Dillard, LW; Doe, CP; Guo, J; Harrison, RK; Ishchenko, A; Jia, L; Johnson, JA; McGeehan, GM; McKeever, BM; Simpson, RD; Singh, SB; Tice, CM; Wu, Z; Xu, Z; Yuan, J; Zhao, W, 2011
)
0.37
"A novel orally bioavailable renin inhibitor, DS-8108b (5), showing potent renin inhibitory activity and excellent in vivo efficacy is described."( Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor.
Chiba, K; Fujimoto, T; Manabe, K; Masubuchi, N; Matsui, Y; Miyazaki, S; Mizuno, M; Nagayama, T; Nakamura, Y; Nishi, T; Ogawa, Y; Sugita, C; Takahashi, M; Tamaki, K, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
fumarate saltAn organic salt derived from fumaric acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
ReninHomo sapiens (human)IC50 (µMol)0.00150.00000.77968.2000AID692715
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID660505Volume of distribution at steady state in cynomolgus monkey at 1 mg/kg, iv and 2 mg/kg, po2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID660513Oral bioavailability in cynomolgus monkey at 2 mg/kg2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID692717Inhibition of cynomolgus monkey plasma renin activity after 60 mins by competitive RIA2012ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9
Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor.
AID660489Half life in cynomolgus monkey at 1 mg/kg, iv2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID298134Partition coefficient, log P at pH 7.42007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
AID692715Inhibition of human recombinant renin compound treated for 10 mins before substrate addition measured after 90 mins by fluorescence method2012ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9
Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor.
AID371788Volume of distribution at steady state in rat at 10 mg/kg, po and 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
AID660355AUC (0 to t) in rat at 10 mg/kg, po2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID660496Clearance in cynomolgus monkey at 1 mg/kg, iv2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID371787Clearance in rat at 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
AID298135Distribution coefficient, log D at pH 6.82007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
AID298142Solubility in phosphate buffer at pH 7.42007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
AID660499Volume of distribution at steady state in rat at 2 mg/kg, iv and 10 mg/kg, po2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID660490Half life in dog at 1 mg/kg, iv2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID660508Oral bioavailability in rat at 10 mg/kg2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID660506Volume of distribution at steady state in dog at 1 mg/kg, iv and 1 mg/kg, po2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID371789Oral bioavailability in rat at 10 mg/kg2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
AID371783Tmax in rat at 10 mg/kg, po and 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
AID692716Inhibition of human plasma renin activity after 60 mins by competitive RIA2012ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9
Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor.
AID298138Dissociation constant, pKa of the compound2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
AID660360AUC (0 to t) in cynomolgus monkey at 2 mg/kg, po2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID371786Half life in rat at 10 mg/kg, po and 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
AID660514Oral bioavailability in dog at 1 mg/kg2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID371785AUC (infinity) in rat at 10 mg/kg, po and 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
AID660497Clearance in dog at 1 mg/kg, iv2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID660492Clearance in rat at 2 mg/kg, iv2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID660361AUC (0 to t) in dog at 1 mg/kg, po2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
AID371782Cmax in rat at 10 mg/kg, po and 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
AID371784AUC (0 to t) in rat at 10 mg/kg, po and 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
AID298136Intrinsic solubility of the compound2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
AID660362Half life in rat at 2 mg/kg, iv2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.11 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index84.36 (26.88)
Search Engine Supply Index1.98 (0.95)

This Compound (56.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]